USANA HEALTH SCIENCES INC — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
On September 30, 2026, USANA Health Sciences amended its Third Amended and Restated Credit Agreement (dated June 27, 2025) with Bank of America. Key changes: (1) EBITDA maintenance covenant reduced from unstated prior level to $100M minimum (or $70M if revolving exposure ≤$50M); (2) asset sale threshold increased from $500K to $2.5M; (3) new exception permitting sale of USANA Australia Pty Ltd's Sydney real property with proceeds at borrower's discretion; (4) clarified sale-leaseback transaction restrictions. Bank of America remains administrative agent and lender. No dollar amount of facility, debt balance, or guarantee amounts disclosed.
Why this rating
Meaningful refinement of debt covenants—lower EBITDA floor suggests operational pressure—but routine amendment. EBITDA covenant of $100M is ~30% of $328M market cap, material relative to size. No new debt drawn. Neutral because amendment could ease near-term covenant risk or signal distress; insufficient context for directional call.
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.